Here we describe the generation and preclinical evaluation of MEDI4166, a dual anti-PCSK9 antibody fused with a GLP-1 analogue agonist peptide, with the potential to provide significant benefit to T2D patients with high cardiovascular risk. Here, PCSK9 is linked to type 2 diabetes mellitus.